Plain-English translation of NCT06484530 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Tuberculosis medications can cause liver damage in some patients, especially those with a specific genetic trait. This trial tests whether identifying patients with that genetic trait (called NAT2 slow acetylator status) and giving them N-acetylcysteine, a protective supplement, can prevent liver damage during TB treatment. The study compares patients who get genetic testing plus the supplement if needed, versus patients who receive standard TB treatment alone.
Liver damage from TB medications happens in up to 60% of patients and can force doctors to pause or stop life-saving treatment. Previous research suggests this medication could help prevent that damage, especially in people with the genetic trait that makes them more vulnerable, but more evidence is needed to confirm this works in practice.
You likely qualify if…
You likely don't qualify if…
If you are assigned to the gene-testing group, you will have a genetic test to determine your NAT2 status. If the test shows you are a slow acetylator (higher risk), you'll take the preventive supplement (600 mg twice daily) for 8 weeks along with your regular TB medications. If you are a rapid or intermediate acetylator, you'll take only your standard TB medications. The other group will receive standard TB treatment without genetic testing. Throughout the study, you'll have follow-up visits to monitor your liver function and track how well the treatment is working.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Thailand